Seattle Genetics to Present at the Cowen 40th Annual Healthcare Conference

BOTHELL, Wash.--(BUSINESS WIRE)-- Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that management will present at the Cowen 40th Annual Healthcare Conference on Tuesday, March 3, 2020 at 9:20 a.m. Eastern Time. The presentation will be webcast live and available for replay from Seattle Genetics’ website at www.seattlegenetics.com in the Investors section.

About Seattle Genetics

Seattle Genetics, Inc. is a global biotechnology company that discovers, develops and commercializes transformative medicines targeting cancer to make a meaningful difference in people’s lives. ADCETRIS® (brentuximab vedotin) and PADCEVTM (enfortumab vedotin-ejfv) use the company’s industry-leading antibody-drug conjugate (ADC) technology. ADCETRIS is approved in certain CD30-expressing lymphomas, and PADCEV is approved in certain metastatic urothelial cancers. In addition, investigational agent tucatinib, a small molecule tyrosine kinase inhibitor, is in late-stage development for HER2-positive metastatic breast cancer and in clinical development for metastatic colorectal cancer. The company is headquartered in Bothell, Washington, and has offices in California, Switzerland and the European Union. For more information on our robust pipeline, visit www.seattlegenetics.com and follow @SeattleGenetics on Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200226005071/en/

Investors:
Peggy Pinkston
(425) 527-4160
[email protected]

Media:
Monique Greer
(425) 527-4641
[email protected]

Source: Seattle Genetics, Inc.

You May Also Be Interested In

• Prime Healthcare Establishes Centers of Excellence for Maternal Care at Saint Mary of Nazareth Hospital and Olympia Fields Hospital
• MotorK Appoints Federico Lozano as Group CFO
• Interactive Brokers Group Reports Brokerage Metrics and Other Financial Information for August 2026, Includes Reg.-NMS Execution Statistics